Article
Chemistry, Analytical
Andrei Hutanu, Chiara Signori, Bernd Moritz, Manuel Gregoritza, Adelheid Rohde, Maria A. Schwarz
Summary: In this study, a capillary electrophoresis-based gel free hybridization assay using fluorescently labeled peptide nucleic acids (PNAs) is proposed to evaluate the identity of nucleic acid species in gene therapy products. Various proof-of-concept studies demonstrate the potential of PNA probes for advanced analytical characterization of therapeutic modalities like oligonucleotides, plasmids, mRNA, and DNA released by recombinant adeno-associated virus. The method is highly specific for single-stranded nucleic acids up to 1000 nucleotides, with a limit of quantification in the picomolar range when multiple probes are used.
ANALYTICAL CHEMISTRY
(2023)
Article
Medicine, General & Internal
Sunita Goyal, John Tisdale, Manfred Schmidt, Julie Kanter, Jennifer Jaroscak, Dustin Whitney, Hans Bitter, Philip D. Gregory, Geoffrey Parsons, Marianna Foos, Ashish Yeri, Maple Gioia, Sarah B. Voytek, Alex Miller, Jessie Lynch, Richard A. Colvin, Melissa Bonner
Summary: A woman developed acute myeloid leukemia 5.5 years after receiving LentiGlobin therapy for sickle cell disease, but investigation revealed that the leukemia was unlikely related to vector insertion. Other genetic mutations and inadequate disease control after treatment may contribute to the development of leukemia in sickle cell disease patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Minori Tamai, Shin Kasai, Koshi Akahane, Thao Nguyen Thu, Keiko Kagami, Chiaki Komatsu, Masako Abe, Atsushi Watanabe, Kumiko Goi, Kunio Miyake, Toshiya Inaba, Junko Takita, Hiroaki Goto, Masayoshi Minegishi, Shotaro Iwamoto, Kanji Sugita, Takeshi Inukai
Summary: In B-cell precursor acute lymphoblastic leukemia (BCP-ALL), somatic mutations of the NR3C1 gene are associated with glucocorticoid resistance, while mutations of the CREBBP and WHSC1 genes are not.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2022)
Article
Virology
Alejandro J. Nicola Candia, Matias Garcia Fallit, Jorge A. Pena Agudelo, Melanie Perez Kuper, Nazareno Gonzalez, Mariela A. Moreno Ayala, Emilio De Simone, Carla Giampaoli, Noelia Casares, Adriana Seilicovich, Juan Jose Lasarte, Flavia A. Zanetti, Marianela Candolfi
Summary: This study found that Foxp3 has protumoral intrinsic effects in breast cancer cells, and gene therapy-mediated blockade of Foxp3 could be a therapeutic strategy to improve the response of these tumors to standard treatment.
Article
Cell Biology
Yan Du, Lan-Lan Li, Feihu Chen, Yan Du
Summary: This study found that SDCBP2 may be a target gene of E2A, and downregulation of SDCBP2 expression can inhibit proliferation and induce differentiation of AML cells. In a mouse model, inhibition of SDCBP2 expression also delayed AML progression.
CELLULAR SIGNALLING
(2023)
Article
Biochemistry & Molecular Biology
Chan Yang, Yan Gu, Zheng Ge, Chunhua Song
Summary: The combination therapy of EZH2 inhibitor DZNeP with BCL-2 inhibitor Venetoclax (Ven) shows synergistic effects and multiple molecular mechanisms in AML cells, promoting apoptosis and inhibiting cell proliferation, reducing leukemia cells, and improving treatment response in patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Laia Cuesta-Casanovas, Jennifer Delgado-Martinez, Josep M. Cornet-Masana, Jose M. Carbo, Antonia Banus-Mulet, Francesca Guijarro, Jordi Esteve, Ruth M. Risueno
Summary: The upregulation of prolactin receptor (PRLR) in acute myeloid leukemia (AML) patients is associated with resistance to the anti-cancer drug cytarabine. The findings suggest that PRLR could be a therapeutic target for AML, and the development of specific PRLR inhibitors could be a potential treatment strategy.
CANCER CELL INTERNATIONAL
(2023)
Article
Multidisciplinary Sciences
William Villiers, Audrey Kelly, Xiaohan He, James Kaufman-Cook, Abdurrahman Elbasir, Halima Bensmail, Paul Lavender, Richard Dillon, Borbala Mifsud, Cameron S. Osborne
Summary: The PML-RARA gene fusion is the characteristic driver of Acute Promyelocytic Leukaemia (APL) and is known to bind to the genome. Here, the authors characterise the impact of PML-RARA on gene regulation in APL cell lines and patient samples using transcriptomics, epigenomics, and machine learning.
NATURE COMMUNICATIONS
(2023)
Article
Cell Biology
Xiancong Yang, Yaoyao Wang, Simin Rong, Jiayue An, Xiaoxu Lan, Baohui Yin, Yunxiao Sun, Pingyu Wang, Boyu Tan, Ye Xuan, Shuyang Xie, Zhenguo Su, Youjie Li
Summary: This study investigates the role of SH3BGRL3 gene and its product circRNA_0010984 in acute myeloid leukemia. The results demonstrate that circSH3BGRL3 promotes leukemia cell proliferation and cell cycle arrest by regulating miR-375 through molecular sponge action, and activates the Hippo signaling pathway involved in malignant tumor proliferation.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Review
Immunology
Vivek P. Chavda, Rajashri Bezbaruah, Disha Valu, Bindra Patel, Anup Kumar, Sanjay Prasad, Bibhuti Bhusan Kakoti, Ajeet Kaushik, Mariya Jesawadawala
Summary: The COVID-19 breakout had a devastating impact globally, resulting in millions of deaths and significant economic burdens. However, the determination of the SARS-CoV-2 genetic sequence and global efforts to develop potential vaccines have provided a glimmer of hope. Adenoviral vector-based vaccines have shown promise due to their higher immune response, better manufacturing processes, safety, efficacy, and manageable storage procedures. As of April 2022, the WHO has approved three adenoviral vector-based vaccines, among a total of 10 vaccines approved worldwide for COVID-19.
Article
Pharmacology & Pharmacy
Xibao Yu, Xin Liu, Xuan Liu, Shuang Jin, Mengjun Zhong, Dingrui Nie, Xiangbo Zeng, Xianfeng Wang, Jiaxiong Tan, Yangqiu Li, Chengwu Zeng
Summary: CASP1/GSDMD expression is lower in patients with acute promyelocytic leukemia (APL) and most other subtypes of primary de novo acute myeloid leukemia (AML), but is increased in all-trans-retinoic acid (ATRA)-treated APL cells; ATRA induces CASP1 expression via the IFN gamma/STAT1 pathway and triggers pyroptotic cell death and differentiation in APL cells, serving as a suppressor in APL progression.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Article
Multidisciplinary Sciences
Shwan Majid Ahmad, Basima Sadq Ahmed, Karzan Ghafur Khidhir, Heshu Sulaiman Rahman
Summary: KLK10 mRNA expression is significantly decreased in pediatric ALL patients and further reduced after receiving chemotherapy for a period of time. Additionally, KLK10 mRNA expression shows high efficiency in discriminating ALL patients from normal counterparts.
Article
Oncology
Bradley Stockard, Neha Bhise, Miyoung Shin, Joy Guingab-Cagmat, Timothy J. Garrett, Stanley Pounds, Jatinder K. Lamba
Summary: The study reveals that metabolic differences in AML cells contribute to drug resistance and may potentially serve as predictive biomarkers for chemosensitivity to various anti-leukemic drugs. These results provide an opportunity to further explore these metabolites in patient samples for association with clinical response.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Xuejie Jiang, Ling Jiang, Jiaying Cheng, Fang Chen, Jinle Ni, Changxin Yin, Qiang Wang, Zhixiang Wang, Dan Fang, Zhengshan Yi, Guopan Yu, Qingxiu Zhong, Bing Z. Carter, Fanyi Meng
Summary: The study investigated the antileukemia effects of HDAC inhibitor chidamide in AML cells and its synergistic activity with the cytotoxic agent adriamycin. Chidamide suppressed EZH2, H3K27me3, and DNMT3A levels, exerted potential antileukemia activity, and increased sensitivity to adriamycin by disrupting the Smo/Gli-1 pathway and downstream signaling target p-AKT. Inhibition of EZH2 by chidamide or shEZH2 enhanced the antileukemia activity of adriamycin in vitro and in vivo.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Review
Medicine, General & Internal
Cristina Panuzzo, Aleksandar Jovanovski, Muhammad Shahzad Ali, Daniela Cilloni, Barbara Pergolizzi
Summary: Efforts made in the last decade regarding the molecular landscape of acute myeloid leukemia (AML) have opened up possibilities for personalized treatment. The improvement in accurate diagnosis and assessment of minimal residual disease (MRD) has led to an increase in new markers suitable for novel and targeted therapies. Metabolomics has emerged as a relevant approach for risk stratification and improvement of targeted therapies.
JOURNAL OF CLINICAL MEDICINE
(2022)
